BETATREX (betamethasone valerate) by Merck & Co. is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. Approved for atopic dermatitis, hand eczema, psoriasis. First approved in 1983.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
BETATREX is a topical corticosteroid ointment containing betamethasone valerate approved in 1983 for inflammatory dermatological conditions. It works through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms, with absorption and metabolism following systemic corticosteroid pathways after percutaneous penetration. The drug treats atopic dermatitis, hand eczema, and psoriasis by reducing skin inflammation and associated symptoms.
As a legacy topical steroid nearing LOE, BETATREX faces significant competitive pressure and likely operates with a lean, maintenance-focused commercial team rather than growth-stage expansion.
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Worked on BETATREX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
BETATREX offers limited career growth opportunity as a legacy topical corticosteroid in terminal decline, with zero linked job openings and a team structure optimized for managed decline rather than innovation. Professionals seeking high-impact roles or advancement should consider opportunities with newer mechanism-based competitors or different therapeutic areas.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo